These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9726723)

  • 1. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia.
    Cazzola M; Imperatore F; Salzillo A; Di Perna F; Calderaro F; Imperatore A; Matera MG
    Chest; 1998 Aug; 114(2):411-5. PubMed ID: 9726723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
    Hanrahan JP; Grogan DR; Baumgartner RA; Wilson A; Cheng H; Zimetbaum PJ; Morganroth J
    Medicine (Baltimore); 2008 Nov; 87(6):319-328. PubMed ID: 19011503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.
    Guhan AR; Cooper S; Oborne J; Lewis S; Bennett J; Tattersfield AE
    Thorax; 2000 Aug; 55(8):650-6. PubMed ID: 10899240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
    Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
    Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
    Celik G; Kayacan O; Beder S; Durmaz G
    Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
    Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
    Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
    Condemi JJ
    Clin Ther; 2001 Sep; 23(9):1529-41. PubMed ID: 11589265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
    Richter K; Janicki S; Jörres RA; Magnussen H
    Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
    Lipworth BJ; Dempsey OJ; Aziz I
    Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients.
    Tötterman KJ; Huhti L; Sutinen E; Backman R; Pietinalho A; Falck M; Larsson P; Selroos O
    Eur Respir J; 1998 Sep; 12(3):573-9. PubMed ID: 9762782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma.
    Pohunek P; Matulka M; Rybnícek O; Kopriva F; Honomichlová H; Svobodová T
    Pediatr Allergy Immunol; 2004 Feb; 15(1):32-9. PubMed ID: 14998380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients.
    Eryonucu B; Uzun K; Güler N; Tuncer M; Sezgi C
    Chest; 2005 Sep; 128(3):1136-9. PubMed ID: 16162698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease.
    Cazzola M; Santangelo G; Piccolo A; Salzillo A; Matera MG; D'Amato G; Rossi F
    Pulm Pharmacol; 1994 Apr; 7(2):103-7. PubMed ID: 7915921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
    Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
    Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of salmeterol xinafoate in the treatment of COPD.
    Mahler DA; Donohue JF; Barbee RA; Goldman MD; Gross NJ; Wisniewski ME; Yancey SW; Zakes BA; Rickard KA; Anderson WH
    Chest; 1999 Apr; 115(4):957-65. PubMed ID: 10208192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.